neoadjuvant chemotherapy


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

neoadjuvant chemotherapy

Chemotherapy given before cancer surgery with the hope that it will shrink the tumour, resulting in a procedure that is less drastic and has clearer margins.

Indications
Breast, colorectal, lung cancers.

Adverse effects
Nausea, vomiting, hair loss, fatigue, oral ulcers, infection, anaemia, increased bleeding.

neoadjuvant chemotherapy

Induction chemotherapy, neoadjuvant therapy, preemptive chemotherapy, primary chemotherapy Oncology 1. The use of chemotherapy on solid–ie, non-hematopoietic neoplasms–eg, osteosarcomas, anal cancer, head&neck cancer; NC is used in Pts with clinically resectable but locally advanced disease that is not amenable to complete eradication surgery or RT; agents used in NC include cisplatin, 5-FU, vinblastine, and the M-VAC 'cocktail.' See Neoadjuvant therapy. Cf Induction therapy.

Neoadjuvant chemotherapy

Treatment of the tumor with drugs before surgery to reduce the size of the tumor.
Mentioned in: Neuroblastoma
References in periodicals archive ?
The similar complication rates demonstrate that undergoing ERAS programs is safe for patients who received preoperative neoadjuvant chemotherapy (9.
George J et al used both WHO and RECIST criteria for response assessment after neoadjuvant chemotherapy in their study of single nucleotide polymorphism in MDR 1 gene in breast cancer.
Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer.
Neoadjuvant chemotherapy regimen, included adriamycin 60mg/m2, with cyclophos-phamide 600mg/m2, over every 3 weeks, for total of 4 cycles, followed by docetaxel 100mg/m2 over every 3 weeks, for another 4 cycles.
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) Clinical Trial.
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Outcomes for neoadjuvant chemotherapy versus primary cytoreduction
The first, published in 2010 showed that survival was similar for women with stage IIIC or IV ovarian cancer treated with either neoadjuvant chemotherapy followed by interval debulking surgery or with primary surgery followed by chemotherapy.
The benefit of neoadjuvant chemotherapy is also noticed in our presented case.
Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
The current treatment algorithm for localized (nonmetastatic) osteosarcoma of the extremity includes neoadjuvant chemotherapy prior to wide local excision most often with limb-salvage and reconstruction and subsequent adjuvant chemotherapy.